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THE CORONAVIRUS INFECTION OUTBREAKS
This century has seen the emergence of three novel b
coronavirus (CoV), namely the severe acute respiratory
syndrome CoV (SARS-CoV-1), the Middle East respira-
tory syndrome CoV (MERS-CoV) and, most recently,
the novel SARS-CoV-2 (COVID-19) that cause severe
human diseases and death. Between November 2002
and August 2003, the global SARS-CoV-1 spread to 32
countries with a mortality rate of 10.87%. Between
April and December 2012, the MERS-CoV spread to
27 countries affecting 2,496 individuals and causing
868 deaths1. The COVID-19 virus spread even more
rapidly constituting a global pandemic with over
6.5 million individuals infected and nearly 400,000
deaths worldwide as of June 20202.
The spread of the 2003 SARS outbreak was primar-
ily nosocomial largely affecting healthcare workers
caring for sick individuals2. However, SARs-CoV-2
spreads by contact with individuals in the early phase
of illness accounting for the higher transmissibility.
Critically, high percentages of COVID-19 patients
with mild symptoms are often missed making the
potential for unknown contact much higher. In addi-
tion, the short serial interval (4–9 days) and the var-
ied reproduction number (R0) of the COVID-19 virus
across the globe supports the potential for transmis-
sion by asymptomatic carriers1.
DIAGNOSIS OF COVID-19
Extensive research is ongoing to develop tests that
would allow healthcare professionals and public
health workers to detect and isolate people with
COVID-19 infection including asymptomatic people
to contain the spread of the disease. The current gold
standard for COVID-19 diagnosis is real-time
polymerase chain reaction (RT-PCR) detection of
SARS-CoV-2 from nasopharyngeal swabs. Acceptable
alternative sample includes a nasal mid-turbinate
swab by healthcare workers or onsite self-collection
using a flocked tapered swab. However, several stud-
ies report a low sensitivity of these samples for detect-
ing SARS-CoV-23,4. In addition, close contact at the
time of collection increases the exposure risk to
healthcare workers4.
SALIVA IS A HIGHLY SENSITIVE SPECIMEN FOR
SARS-COV-2/COVID-19 DETECTION
A high concordance between the saliva and the
nasopharyngeal swabs as specimens for laboratory
diagnosis of respiratory viruses including the SARS-
CoV-1 is well established3. Earlier this year, during the
initial outbreak in China, To et al.5 assessed the saliva
of 12 nasopharyngeal swab-confirmed COVID-19
patients between 0 and 7 days of hospitalization for
SARS-CoV-2 as determined by RT-PCR. They
reported a median viral load in the first saliva samples
of 3.3 9 106 copies/mL with a range of 9.9 9 102 and
1.2 9 108 copies/mL5. More recently, a study at the
Yale New Haven Hospital compared the saliva and
paired nasopharyngeal swabs from 38 severely dis-
eased COVID-19 patients. The SARS-CoV-2 titer from
the saliva was significantly higher than that from the
nasopharyngeal swabs4. Significantly, preliminary
reports support the use of saliva for detection of pre-
symptomatic or asymptomatic individuals albeit at
lower titers of SARS-COV-2 (104–105 copies/mL)4,6.
Temporal profile of SARS-CoV2 in saliva
In general, the viral titer in a biospecimen is expected
to decrease with recovery from disease. However,
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longitudinal testing of nasopharyngeal swabs for
SARS-CoV-2 yielded many false–negative results, with
positive reports following previous negative reports.
In contrast, in a pilot study by Wyllie et al.4, serial
saliva samples from 12 severely ill COVID-19 patients
exhibited progressively decreasing SARS-CoV-2 titers.
Interestingly, To et al. reported that in infected and
recovered COVID-19 patients, the saliva was positive
for SARS-CoV-2 even at 25 days after the first symp-
toms and that the titer was higher in the post-recovery
saliva of patients who had experienced severe dis-
ease3,6.
Oral epithelial cells as reservoirs of SARS-CoV-2
The initial step of COVID-19 infection is its entrance
into human cells. Several studies suggest that similar
to SARS-CoV-1, SARS-CoV-2 exploits the angiotensin
converting enzyme 2 (ACE2) as receptor to gain
access to target cells. The spike protein of SARS-CoV-
2 envelope binds the membrane bound ACE2, and the
strength of this interaction as the initial step of attach-
ment determines the susceptibility to infection. In
humans, ACE2 is predominantly observed in epithelial
cells in contact with the environment, although
expression has also been reported in internal organs
including kidney and heart. In general, the mode of
transmission and the distribution of ACE2 expression
in different tissues of the human body influence the
route of infection, symptoms and outcome of COVID-
197. Thus, the spread by droplets and the abundant
ACE2 expression in the alveolar epithelial cells of the
lungs supports the high incidence of respiratory
pathology in COVID-19 patients.
Based on the analyses of two public RNA sequence
databases, Xu et al.8 reported that the ACE2 was
differentially expressed in the oral mucosa in different
sites, with the highest expression in the tongue and
floor of the mouth. They confirmed the high expres-
sion of ACE2 in oral epithelial cells by single cell
transcriptome analysis of normal oral mucosal biop-
sies. Interestingly, a high expression of ACE2 has also
been reported in the granular cells and the ductal
epithelial cells of the salivary glands9. In this context,
it is interesting to note that Chen et al.10 reported
high titers of SARS-CoV2 in pure saliva collected
from salivary gland duct of severely ill COVID-19
patients.
Collectively, these findings support a potential role
for oral and salivary gland epithelial cells as COVID-
19 reservoirs or as initial sites of infection. We and
others have shown that the saliva is a rich source of
viable oral epithelial cells11. Viral shedding by
infected epithelial cells could contribute to the higher
sensitivity of COVID-19 detection in the saliva of
asymptomatic, pre-symptomatic and post-recovery
individuals.
Oral-fecal transmission of SARS-CoV-2
Emerging clinical data suggest that a portion of
COVID-19 patients may present with abdominal dis-
comfort, diarrhea and other gastrointestinal symp-
toms. SARS-CoV-2 virus has been consistently
detected in feces of COVID-19 patients. Because the
rectal epithelial cells express high levels of ACE2, it is
suggested that the viral entry, replication and shed-
ding from these cells account for the high titers of
SARS-CoV2 in feces12. In this context, oral–fecal
communication and self-inoculation have been sug-
gested as alternative mechanisms for the high titers of
the COVID-19 virus in saliva.
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Figure 1. Saliva and COVID-19. The COVID-19 virus is detected in saliva of severely ill patients at higher sensitivity, as well as in asymptomatic carri-
ers.The oral epithelial cells and the salivary gland ductal epithelial cells that express ACE2, the receptor for the COVID-19 virus, could function as cellular
reservoirs for the virus. Dental healthcare professionals and co-workers are at risk for direct transmission of COVID-19 virus. The virus remains stable on
inanimate surfaces for variable periods of time ranging from a few minutes to few days. Inadvertent transmission can occur by contaminating the instruments,
work-surfaces and cabinets by hands soiled with saliva that repeatedly contact equipment in the operatory.
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Risk of direct transmission
Direct contact by respiratory droplets or aerosols is
the most widely accepted mode of COVID-19 trans-
mission. Use of rotary or surgical instruments such as
handpieces, ultrasonic scalers or air–water syringes in
routine dental practice generates visible spatter and
droplets of saliva and blood13. The distance the dro-
plets travel depends on the size with larger droplets
tending to settle quickly. Very small droplets (<5 µM)
may evaporate, become droplet nuclei or aerosol and
could contribute to the airborne transmission of infec-
tions14. The number and size of saliva droplets gener-
ated not only vary with the dental procedure but also
among people, suggesting heterogeneous transmission
potential. Contamination of clinical gowns and inner
surfaces of masks worn by dental hygienists with sali-
vary droplets has been reported following ultrasonic
cleaning. Although the surgical masks protect the
mucous membrane of the mouth and nose from the
spatter, they do not provide complete protection from
airborne infections13.
Positive airborne transmission is dependent on the
duration of stability of the infectious agent in aerosols
and the susceptibility of the individual in the path of
the aerosols. The observed stability of airborne SARS-
CoV-1 by RT-PCR and in viable cultures suggests
transmission of coronaviruses by short- and long-
range aerosols15,16. As of now, little is known about
the stability of COVID-19 virus in saliva droplets or
aerosols. A study from the University of Nebraska
Medical Center demonstrated that the SARS-CoV-2
genome was not only detectable in air samples from
rooms of COVID-19 patients, but also in 66.7% of
air samples obtained from hallways outside the
patients’ rooms14. Using Bayesian regression model
van Doremalen et al.16 compared the stability of
COVID-19 virus and SARS-CoV-1 in aerosols. They
found that much like the SARS-CoV-1, the COVID-
19 virus remained viable in aerosols throughout the 3-
hour period of experimental duration. Taken together,
these observations substantiate the high risk for direct
airborne transmission of the COVID-19 virus to den-
tal healthcare professionals (Figure 1).
Indirect contact transmission
Clusters of COVID-19 infection in meat processing
plants and church attenders as well as the success of
social distancing in reducing the infection suggest addi-
tional modes of transmission of the airborne virus.
Respiratory droplets are generated by talking, breath-
ing, sneezing and coughing. Often large droplets with
infectious agents deposit on hard surfaces and became
a source of transmission. Indeed, during previous out-
breaks, the SARS-CoV-1 and the MERS-CoV have
been shown to survive on dry metal, ceramic or plastic
surfaces for unusually long periods (4–6 days) at room
temperature. Further, the SARS-CoV1 exhibited a dose
response, being stable on disposable plastic for a short
period of 1 hour following low dose inoculation (104
dose/mL) but survived for 2 days at higher inoculation
concentration (106 dose/mL)15.
The COVID-19 virus is expected to share similar fea-
tures of stability as SARS-CoV1 and MERS-CoV.
Recently, Liu et al.17 analysed 35 aerosol samples from
patient areas and medical staff areas in two hospitals in
Wuhan, China for SARS-CoV2 by digital polymerase
chain reaction. They observed that the droplets depos-
ited on the surfaces of intensive care workstations
tested positive for the virus. van Doremalen et al.16
evaluated the stability in a more controlled environ-
ment and found that much like SARS-CoV-1, the labo-
ratory created COVID-19 aerosols remained stable on
stainless steel and plastic surfaces for 72 hours.
In clinical dental settings, digital contamination,
that is hands soiled with saliva that repeatedly contact
operatory equipment and return to the patient’s
mouth during treatment, can easily increase the area
of contaminated surfaces. This will in turn increase
the chances of transmission to all personnel with
access to the operatory as well as enhance the risk of
cross-contamination between patients for an extended
period (Figure 1).
CONCLUSIONS
To contain the COVID-19 pandemic, it is essential to
find methods that can be used by a wide range of
health care professionals to identify the virus. The less
potential contagious nature of the collection process,
the ease of collection and the convenience of frequent
collection for real-time monitoring makes saliva an
excellent specimen for home-based collection for epi-
demiological investigations. With respect to COVID-
19, the use of saliva offers the added advantages of
greater sensitivity and potential for detection at an
early stage of infection.
However, the advantages from a diagnostic perspec-
tive also reflect the potential risk to dental profession-
als from saliva from infected patients. Although not
validated in COVID-19 patients, but by extension
from studies of SARS-CoV-1 studies, it is suggested
that using antimicrobial mouthrinses such as
chlorhexidine, hydrogen peroxide or sodium
hypochlorite solutions could reduce the viral load in
saliva droplets and reduce the risk of direct transmis-
sion. Because large saliva droplets could deposit on
inanimate surfaces, changing the personal protective
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equipment including the clinical gown, gloves, masks,
protective eye wear and face shield between patients,
as well as decontamination of the work surfaces in
the clinic, could reduce the risk of indirect contact
transmission.
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